Department of Surgery, Keck School of Medicine of USC, Los Angeles, CA.
Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA.
Am J Transplant. 2016 Oct;16(10):2912-2924. doi: 10.1111/ajt.13823. Epub 2016 May 13.
In certain regions of the United States in which organ donor shortages are persistent and competition is high, recipients wait longer and are critically ill with Model for End-Stage Liver Disease (MELD) scores ≥40 when they undergo liver transplantation. Recent implementation of Share 35 has increased the percentage of recipients transplanted at these higher MELD scores. The purpose of our study was to examine national data of liver transplant recipients with MELD scores ≥40 and to identify risk factors that affect graft and recipient survival. During the 12-year study period, 5002 adult recipients underwent deceased donor whole-liver transplantation. The 1-, 3-, 5- and 10-year graft survival rates were 77%, 69%, 64% and 50%, respectively. The 1-, 3-, 5- and 10-year patient survival rates were 80%, 72%, 67% and 53%, respectively. Multivariable analysis identified previous transplant, ventilator dependence, diabetes, hepatitis C virus, age >60 years and prolonged hospitalization prior to transplant as recipient factors increasing the risk of graft failure and death. Donor age >30 years was associated with an incrementally increased risk of graft failure and death. Recipients after implementation of Share 35 had shorter waiting times and higher graft and patient survival compared with pre-Share 35 recipients, demonstrating that some risk factors can be mitigated by policy changes that increase organ accessibility.
在美国某些器官捐献短缺且竞争激烈的地区,接受者等待时间更长,当他们接受肝移植时,患有终末期肝病模型(MELD)评分≥40 的情况更为严重。最近实施的 Share 35 增加了在这些更高 MELD 评分下进行移植的接受者的比例。我们的研究目的是检查 MELD 评分≥40 的肝移植接受者的全国数据,并确定影响移植物和受者生存的风险因素。在 12 年的研究期间,5002 名成年接受者接受了已故供体全肝移植。1、3、5 和 10 年移植物存活率分别为 77%、69%、64%和 50%。1、3、5 和 10 年患者存活率分别为 80%、72%、67%和 53%。多变量分析确定了先前的移植、呼吸机依赖、糖尿病、丙型肝炎病毒、年龄>60 岁以及移植前住院时间延长是增加移植物失败和死亡风险的受者因素。供体年龄>30 岁与移植物失败和死亡风险的增加呈递增关系。与 Share 35 实施前的接受者相比,实施 Share 35 后的接受者等待时间更短,移植物和患者存活率更高,这表明一些风险因素可以通过增加器官可及性的政策变化来减轻。